Phase 3 vs Approved — Immunology Deal Valuation Comparison

Phase 3 deals are more milestone-weighted (74% milestones), reflecting higher clinical risk. Approved deals shift toward higher upfront allocations (39% upfront) as clinical de-risking reduces the need for contingent milestone structures.

The optimal licensing window depends on strategic priorities. Phase 3 assets offer lower entry cost for licensees, while Approved assets provide more certainty. The 150% premium from Phase 3 to Approved reflects the value created by clinical data, making the transition point critical for deal timing.